Horslen S, Barr M L, Christensen L L, Ettenger R, Magee J C
Children's Hospital and Regional Medical Center, Seattle, Washington, USA.
Am J Transplant. 2007;7(5 Pt 2):1339-58. doi: 10.1111/j.1600-6143.2007.01780.x.
Solid organ transplantation is accepted as a standard lifesaving therapy for end-stage organ failure in children. This article reviews trends in pediatric transplantation from 1996 to 2005 using OPTN data analyzed by the Scientific Registry of Transplant Recipients. Over this period, children have contributed significantly to the donor pool, and although the number of pediatric donors has fallen from 1062 to 900, this still accounts for 12% of all deceased donors. In 2005, 2% of 89,884 candidates listed for transplantation were less than 18 years old; in 2005, 1955 children, or 7% of 28,105 recipients, received a transplant. Improvement in waiting list mortality is documented for most organs, but pretransplant mortality, especially among the youngest children, remains a concern. Posttransplant survival for both patients and allografts similarly has shown improvement throughout the period; in most cases, survival is as good as or better than that seen in adults. Examination of immunosuppressive practices shows an increasing tendency across organs toward tacrolimus-based regimens. In addition, use of induction immunotherapy in the form of anti-lymphocyte antibody preparations, especially the interleukin-2 receptor antagonists, has increased steadily. Despite documented advances in care and outcomes for children undergoing transplantation, several considerations remain that require attention as we attempt to optimize transplant management.
实体器官移植被公认为是治疗儿童终末期器官衰竭的标准挽救生命疗法。本文利用移植受者科学登记处分析的器官共享联合网络(OPTN)数据,回顾了1996年至2005年期间儿科移植的趋势。在此期间,儿童对供体库做出了重大贡献,尽管儿科供体数量已从1062例降至900例,但这仍占所有已故供体的12%。2005年,在89884名登记等待移植的候选人中,2%的人年龄小于18岁;2005年,1955名儿童(占28105名受者的7%)接受了移植。大多数器官的等待名单死亡率有所改善,但移植前死亡率,尤其是最年幼的儿童中的移植前死亡率,仍然令人担忧。在此期间,患者和同种异体移植物的移植后存活率同样有所提高;在大多数情况下,存活率与成人相当或更高。对免疫抑制方案的检查表明,各器官使用基于他克莫司的方案的趋势在增加。此外,以抗淋巴细胞抗体制剂形式使用诱导免疫疗法,尤其是白细胞介素-2受体拮抗剂,一直在稳步增加。尽管有记录表明接受移植的儿童在护理和治疗结果方面取得了进展,但在我们试图优化移植管理时,仍有几个问题需要关注。